KRAS testing in metastatic colorectal cancer

Implications on the use of biologic agents

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Colorectal cancer is a significant healthcare problem in the United States, with meaningful improvement in survival over the past few years. Much of that improvement is attributable to the availability of molecularly targeted therapies, such as inhibitors of the vascular endothelial growth factor (bevacizumab) and epidermal growth factor receptor (cetuximab and panitumumab), in addition to active cytotoxic agents. KRAS mutations have long been described to play an adverse prognostic role in colorectal cancer. KRAS is downstream from EGFR, and oncogenic mutations will yield a constitutively active protein that will override EGFR control of downstream signaling. Such mutations in KRAS would therefore confer resistance to anti-EGFR antibodies. The cumulative results of several trials incorporating more than a thousand patients in studies of cetuximab and panitumumab confirm that the presence of KRAS mutation in tumors is highly predictive of resistance to anti-EGFR therapy. These findings are likely to change the landscape of metastatic CRC treatment by providing an improved patient-tailored approach.

Original languageEnglish (US)
Pages (from-to)135-140
Number of pages6
JournalClinical Colorectal Cancer
Volume8
Issue number3
DOIs
StatePublished - Jul 1 2009
Externally publishedYes

Fingerprint

Biological Factors
Colorectal Neoplasms
Mutation
Cytotoxins
Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor A
Anti-Idiotypic Antibodies
Therapeutics
Delivery of Health Care
Survival
Neoplasms
Proteins
Cetuximab
panitumumab

Keywords

  • Bevacizumab
  • Cetuximab
  • Epidermal growth factor receptor
  • Panitumumab

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

KRAS testing in metastatic colorectal cancer : Implications on the use of biologic agents. / Bekaii-Saab, Tanios.

In: Clinical Colorectal Cancer, Vol. 8, No. 3, 01.07.2009, p. 135-140.

Research output: Contribution to journalReview article

@article{b1b1a920ef1f40b2aef35cbb4498755b,
title = "KRAS testing in metastatic colorectal cancer: Implications on the use of biologic agents",
abstract = "Colorectal cancer is a significant healthcare problem in the United States, with meaningful improvement in survival over the past few years. Much of that improvement is attributable to the availability of molecularly targeted therapies, such as inhibitors of the vascular endothelial growth factor (bevacizumab) and epidermal growth factor receptor (cetuximab and panitumumab), in addition to active cytotoxic agents. KRAS mutations have long been described to play an adverse prognostic role in colorectal cancer. KRAS is downstream from EGFR, and oncogenic mutations will yield a constitutively active protein that will override EGFR control of downstream signaling. Such mutations in KRAS would therefore confer resistance to anti-EGFR antibodies. The cumulative results of several trials incorporating more than a thousand patients in studies of cetuximab and panitumumab confirm that the presence of KRAS mutation in tumors is highly predictive of resistance to anti-EGFR therapy. These findings are likely to change the landscape of metastatic CRC treatment by providing an improved patient-tailored approach.",
keywords = "Bevacizumab, Cetuximab, Epidermal growth factor receptor, Panitumumab",
author = "Tanios Bekaii-Saab",
year = "2009",
month = "7",
day = "1",
doi = "10.3816/CCC.2009.n.022",
language = "English (US)",
volume = "8",
pages = "135--140",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - KRAS testing in metastatic colorectal cancer

T2 - Implications on the use of biologic agents

AU - Bekaii-Saab, Tanios

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Colorectal cancer is a significant healthcare problem in the United States, with meaningful improvement in survival over the past few years. Much of that improvement is attributable to the availability of molecularly targeted therapies, such as inhibitors of the vascular endothelial growth factor (bevacizumab) and epidermal growth factor receptor (cetuximab and panitumumab), in addition to active cytotoxic agents. KRAS mutations have long been described to play an adverse prognostic role in colorectal cancer. KRAS is downstream from EGFR, and oncogenic mutations will yield a constitutively active protein that will override EGFR control of downstream signaling. Such mutations in KRAS would therefore confer resistance to anti-EGFR antibodies. The cumulative results of several trials incorporating more than a thousand patients in studies of cetuximab and panitumumab confirm that the presence of KRAS mutation in tumors is highly predictive of resistance to anti-EGFR therapy. These findings are likely to change the landscape of metastatic CRC treatment by providing an improved patient-tailored approach.

AB - Colorectal cancer is a significant healthcare problem in the United States, with meaningful improvement in survival over the past few years. Much of that improvement is attributable to the availability of molecularly targeted therapies, such as inhibitors of the vascular endothelial growth factor (bevacizumab) and epidermal growth factor receptor (cetuximab and panitumumab), in addition to active cytotoxic agents. KRAS mutations have long been described to play an adverse prognostic role in colorectal cancer. KRAS is downstream from EGFR, and oncogenic mutations will yield a constitutively active protein that will override EGFR control of downstream signaling. Such mutations in KRAS would therefore confer resistance to anti-EGFR antibodies. The cumulative results of several trials incorporating more than a thousand patients in studies of cetuximab and panitumumab confirm that the presence of KRAS mutation in tumors is highly predictive of resistance to anti-EGFR therapy. These findings are likely to change the landscape of metastatic CRC treatment by providing an improved patient-tailored approach.

KW - Bevacizumab

KW - Cetuximab

KW - Epidermal growth factor receptor

KW - Panitumumab

UR - http://www.scopus.com/inward/record.url?scp=69549122299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69549122299&partnerID=8YFLogxK

U2 - 10.3816/CCC.2009.n.022

DO - 10.3816/CCC.2009.n.022

M3 - Review article

VL - 8

SP - 135

EP - 140

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 3

ER -